The vaccine, Skycellflu Quadrivalent Prefilled Syringe, is the first Korean vaccine to be approved in the world's fourth most populous country.
The World Health Organization predicts the circulating strains of influenza for both the Northern and Southern Hemispheres each year. Indonesia is influenced by vaccination guidelines for both hemispheres.
This approval was for the Northern Hemisphere influenza vaccine, the Korean drugmaker said, adding that it anticipates swift approval for the Southern Hemisphere version by Indonesian health authorities.
Among the influenza vaccines available in Korea, Skycellflu is the only one that uses a cell culture method. It has already been approved in Malaysia, Thailand, Iran and Chile.
"It is very encouraging that our own developed vaccines are receiving approvals worldwide, a significant step for expanding our global export market," CEO Ahn Jae-yong said.
"We are confident that SK bioscience will continue to grow into a global vaccine brand beyond Korea, as our vaccines, including shingles, chickenpox and typhoid vaccines, are securing WHO prequalification certifications and global approvals one after another."
